浙江大学 | 药学院 | English Version
     
     
表的文章与开展的学术交流

    发表的论文

    * Corresponding Authorship

    # Co-first Authorship

  1. J. Tang, J. B. Fu, Y. X. Wang, B. Li, Y. H. Li, Q. X. Yang, X. J. Cui, J. J. Hong, X. F. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. ANPELA: analysis and performance-assessment of the label-free quantification workflow for metaproteomic studies. Brief Bioinform (当年影响因子: 7.065, 生物一区 TOP 期刊). BIB-18-0245, accepted (2018).
  2. Y. H. Li, C. Y. Yu, X. X. Li, P. Zhang, J. Tang, Q. X. Yang, T. T. Fu, X. Y. Zhang, X. J. Cui, G. Tu, Y. Zhang, S. Li, F. Y. Yang, Q. Sun, C. Qin, X. Zeng, Z. Chen, Y. Z. Chen*, F. Zhu*. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res (当年影响因子: 11.561, 生物一区 TOP 期刊). 46(D1): 1121-1127 (2018).
  3. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.36% in 2018.
    领域内专家评论:
    • Introduced by OMICTOOLS as "useful for facilitating patient focused research, discovery and clinical investigations of the targeted therapeutics".

  4. J. B. Fu, J. Tang, Y. X. Wang, X. J. Cui, Q. X. Yang, J. J. Hong, X. X. Li, S. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. Discovery of the consistently well-performed analysis chain for SWATH-MS based pharmacoproteomic quantification. Front Pharmacol (当年影响因子: 4.400, 医学二区期刊). 9: 681 (2018).
  5. F. Zhu*, X. X. Li, S. Y. Yang, Y. Z. Chen*. The clinical success of drug targets prospectively predicted by the in-silico study. Trends Pharmacol Sci (当年影响因子: 12.797, 医学一区 TOP 期刊). 39(3): 229-231 (2018).
  6. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.21% in 2018.

  7. Z. J. Han, W. W. Xue, L. Tao, F. Zhu*. Identification of novel immune-relevant drug target genes for alzheimer's disease by combining ontology inference with network analysis. CNS Neurosci Ther (当年影响因子: 3.495, 医学二区期刊). 24(12):1253-1263 (2018).
  8. 封面论文:

  9. F. Y. Yang, G. X. Zheng, T. T. Fu, X. F. Li, G. Tu, Y. H. Li, X. J. Yao, W. W. Xue*, F. Zhu*. Prediction of binding mode and resistance profile for dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase associated ribonuclease H. Phys Chem Chem Phys (当年影响因子: 4.123, 化学二区 TOP 期刊). 20(37):23873-23884 (2018).
  10. 封底论文:

  11. X. X. Li, J. Y. Yin, J. Tang, Y. H. Li, Q. X. Yang, Z. Y. Xiao, R. Y. Zhang, Y. X. Wang, J. J. Hong, L. Tao, W. W. Xue, F. Zhu*. Determining the balance between drug efficacy and safety by the network and biological system profile of its therapeutic target. Front Pharmacol (当年影响因子: 4.400, 医学二区期刊). 9:1245 (2018).
  12. T. T. Fu, G. X. Zheng, G. Tu, F. Y. Yang, Y. Z. Chen, X. J. Yao, X. F. Li, W. W. Xue*, F. Zhu*. Exploring the binding mechanism of metabotropic glutamate receptor 5 negative allosteric modulators in clinical trials by molecular dynamics simulations. ACS Chem Neurosci (当年影响因子: 4.211, 化学二区 TOP 期刊). 9(6): 1492-1502 (2018).
  13. W. W. Xue, P. P. Wang, G. Tu, F. Y. Yang, G. X. Zheng, X. F. Li, X. X. Li, Y. Z. Chen, X. J. Yao, F. Zhu*. Computational identification of the binding mechanism of triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. Phys Chem Chem Phys (当年影响因子: 4.123, 化学二区 TOP 期刊). 20(9): 6606-6616 (2018).
  14. W. W. Xue, F. Y. Yang, P. P. Wang, G. X. Zheng, Y. Z. Chen, X. J. Yao, F. Zhu*. What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation. ACS Chem Neurosci (当年影响因子: 4.211, 化学二区 TOP 期刊). 9(5): 1128-1140 (2018).
  15. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 1.11% in 2018.

  16. W. W. Xue*, T. T. Fu, G. X. Zheng, G. Tu, Y. Zhang, F. Y. Yang, L. Tao, L. X. Yao, F. Zhu*. Recent advances and challenges of the drugs acting on monoamine transporters. Curr Med Chem (当年影响因子: 3.469, 医学二区期刊). doi: 10.2174/0929867325666181009123218 (2018).
  17. G. X. Zheng, F. Y. Yang, T. T. Fu, G. Tu, Y. Z. Chen, X. J. Yao, W. W. Xue*, F. Zhu*. Computational characterization of the selective inhibition of human norepinephrine and serotonin transporters by escitalopram scaffold. Phys Chem Chem Phys (当年影响因子: 4.123, 化学二区 TOP 期刊). 20(46): 29513-29527 (2018).
  18. C. Y. Yu, X. X. Li, H. Yang, Y. H. Li, W. W. Xue, Y. Z. Chen, L. Tao, F. Zhu*. Assessing the performances of protein function prediction algorithms from the perspectives of identification accuracy and false discovery rate. Int J Mol Sci (当年影响因子: 3.687, 化学三区期刊). 19(1): 183 (2018).
  19. J. Tang, Y. Zhang, J. B. Fu, Y. X. Wang, Y. Li, Q. X. Yang, L. X. Yao, W. W. Xue*, F. Zhu*. Computational advances in the label-free quantification of cancer proteomics data. Curr Pharm Des (当年影响因子: 2.757, 化学三区期刊). doi: 10.2174/1381612824666181102125638 (2018).
  20. G. Tu, T. T. Fu, F. Y. Yang, L. X. Yao, W. W. Xue*, F. Zhu*. Prediction of GluN2B-CT1290-1310/DAPK1 interaction by protein-peptide docking and molecular dynamics simulation. Molecules (当年影响因子: 3.098, 化学三区期刊). 23(11): 3018 (2018).
  21. X. F. Li, X. X. Li, Y. H. Li, C. Y. Yu, W. W. Xue, J. Hu*, B. Li, P. P. Wang, F. Zhu*. What makes species productive of anti-cancer drugs? Clues from drugs' species origin, druglikeness, target and pathway. Anticancer Agents Med Chem (当年影响因子: 2.556, 医学三区期刊). doi: 10.2174/1871520618666181029132017 (2018).
  22. C. Shen, Z. Wang, X. J. Yao, T. L. Lei, E. C. Wang, Z. Y. Tian, F. Zhu, D. Li, T. J. Hou*. Comprehensive assessment of nine docking programs on Type II Kinase Inhibitors: prediction accuracy of sampling power, scoring power and screening power. Brief Bioinform (当年影响因子: 6.302, 生物一区 TOP 期刊). doi: 10.1093/bib/bby103 (2018).
  23. Z. Wang, X. W. Wang, Y. Y. Li, T. L. Lei, E. C. Wang, D. Li, Y. Kang, F. Zhu, T. J. Hou*. farPPI: a webserver for accurate prediction of protein-ligand binding structures for small-molecule PPI inhibitors by MM/PB(GB)SA methods. Bioinformatics (当年影响因子: 5.481, 生物二区 TOP 期刊). doi: 10.1093/bioinformatics/bty879 (2018).
  24. H. Y. Chen, W. T. Fu, Z. Wang, X. W. Wang, T. L. Lei, F. Zhu, D. Li, S. Chang, L. Xu, T. J. Hou*. Reliability of docking-based virtual screening for GPCR ligands with homology modeled structures: a case study of angiotensin II type I receptor. ACS Chem Neurosci (当年影响因子: 4.211, 化学二区期刊). doi: 10.1021/acschemneuro.8b00489 (2018).
  25. P. C. Pan, J. Chen, X. J. Li, M. Y. Li, H. D. Yu, J. Zhao, J. Ni, X. W. Wang, H. Y. Sun, S. Tian, F. Zhu, F. Liu, Y. Huang, T. J. Hou*. Structure-based drug design and identification of H2O-soluble and low toxic hexacyclic camptothecin derivatives with improved efficacy in both cancer and lethal inflammation models in vivo. J Med Chem (当年影响因子: 6.253, 医学二区 TOP 期刊). 61(19): 8613-8624 (2018).
  26. F. Chen, H. Y. Sun, J. M. Wang, F. Zhu, H. Liu, Z. Wang, T. L. Lei, Y. Y. Li, T. J. Hou*. Assessing the performance of MM/PBSA and MM/GBSA methods. 8. Predicting binding free energies and poses of protein-RNA complexes. RNA (当年影响因子: 4.605, 生物二区期刊). 24(9): 1183-1194 (2018).
  27. J. Shang, B. Hu, J. M. Wang, F. Zhu, Y. Kang, D. Li, H. Y. Sun, D. X. Kong, T. J. Hou*. Cheminformatic insight into the differences between terrestrial and marine originated natural products. J Chem Inf Model (当年影响因子: 3.804, 化学二区期刊). 58(6): 1182-1193 (2018).
  28. H. Y. Sun, F. Chen, H. Liu, Z. Wang, P. C. Chen, F. Zhu, T. J. Hou*. Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. Phys Chem Chem Phys (当年影响因子: 4.123, 化学二区 TOP 期刊). 20(21):14450-14460 (2018).
  29. X. T. Kong, H. Y. Sun, P. C. Pan, F. Zhu, S. Chang, L. Xu, Y. Y. Li, T. J. Hou*. Importance of protein flexibility on molecular recognition: a case study on type-I1/2 inhibitors of ALK. Phys Chem Chem Phys (当年影响因子: 4.123, 化学二区 TOP 期刊). 20(7): 4851-4863 (2018).
  30. B. Li, J. Tang, Q. X. Yang, S. Li, X. J. Cui, Y. H. Li, Y. Z. Chen, W. W. Xue, X. F. Li, F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Res (当年影响因子: 10.162, 生物一区 TOP 期刊). 45(W1): 162-170 (2017).
  31. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.98% in 2018.
    领域内专家评论:
    • Introduced by OMICTOOLS as "provided valuable guidance to the selection of suitable algorithm in metabolomics".
    • Discussed in StackExchange as "works fine" and "corrections for batches without QC options".

  32. P. P. Wang, X. Y. Zhang, T. T. Fu, S. Li, B. Li, W. W. Xue*, X. J. Yao, Y. Z. Chen, F. Zhu*. Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chem Neurosci (当年影响因子: 4.348, 化学二区 TOP 期刊). 8(6): 1416-1428 (2017).
  33. G. X. Zheng, W. W. Xue*, F. Y. Yang, Y. Zhang, Y. Z. Chen, X. J. Yao, F. Zhu*. Revealing vilazodone's binding mechanism underlying its partial agonism to 5-HT1A receptor in the treatment of major depressive disorder. Phys Chem Chem Phys (当年影响因子: 4.449, 化学二区 TOP 期刊). 19(42): 28885-28896 (2017).
  34. P. P. Wang, T. T. Fu, X. Y. Zhang, F. Y. Yang, G. X. Zheng, W. W. Xue*, Y. Z. Chen, X. J. Yao, F. Zhu*. Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. BBA Gen Subjects (当年影响因子: 5.083, 生物二区期刊). 1861(11A): 2766-2777 (2017).
  35. F. Y. Yang, T. T. Fu, X. Y. Zhang, J. Hu*, W. W. Xue*, G. X. Zheng, B. Li, Y. H. Li, X. J. Yao, F. Zhu*. Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters. Mol Simul (当年影响因子: 1.678, 化学四区期刊). 43(13-16): 1089-1098 (2017).
  36. P. C. Pan, H. D. Yu, Q. L. Liu, X. T. Kong, H. Chen, J. A. Chen, Q. Liu, D. Li, Y. Kang, H. Y. Sun, W. F. Zhou, S. Tian, S. L. Cui, F. Zhu, Y. Y. Li, Y. Huang, T. J. Hou*. Combating drug-resistant mutants of ALK with potent and selective type-I1/2 inhibitors by stabilizing unique DFG-shifted loop conformation. ACS Cent Sci (当年影响因子: 7.939, 化学一区 TOP 期刊). 3(11): 1208-1220 (2017).
  37. T. Feng, F. Chen, Y. Kang, H. Y. Sun, H. Liu, D. Li, F. Zhu, T. J. Hou*. HawkRank: a new scoring function for protein-protein docking based on weighted energy terms. J Cheminform (当年影响因子: 4.220, 化学二区 TOP 期刊). 9(1): 66 (2017).
  38. T. L. Lei, H. Y. Sun, Y. Kang, F. Zhu, H. Liu, W. F. Zhou, Z. Wang, D. Li, Y. Y. Li, T. J. Hou*. ADMET evaluation in drug discovery. 18. Reliable prediction of chemical-induced urinary tract toxicity by boosting machine learning approaches. Mol Pharmaceut (当年影响因子: 4.440, 医学二区期刊). 14(11): 3935-3953 (2017).
  39. S. Tian, X. Wang, L. L. Li, X. H. Zhang, Y. Y. Li, F. Zhu, T. J. Hou*, X. C. Zhen*. Discovery of novel and selective adenosine A2A receptor antagonists for treating parkinson's disease through comparative structure-based virtual screening. J Chem Inf Model (当年影响因子: 3.760, 化学二区期刊). 57(6): 1474-1487 (2017).
  40. X. T. Kong, H. Y. Sun, P. C. Pan, D. Li, F. Zhu, S. Chang, L. Xu, Y. Y. Li*, T. J. Hou*. How does the L884P mutation confer resistance to type-II inhibitors of JAK2 kinase: a comprehensive molecular modeling study. Sci Rep (当年影响因子: 4.259, 综合性三区期刊). 7(1): 9088 (2017).
  41. J. Y. An, X. D. Pei, Z. L. Zang, Z. Zhou, J. T. Hu, X. Zheng, Y. Zhang, J. J. He, L. Duan, R. F. Shen, W. H. Zhang, F. Zhu, S. Li*, H. Yang*. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. Oncotarget (当年影响因子: 5.168, 医学二区期刊). 8(23): 37538-37549 (2017).
  42. P. Zhang, L. Tao, X. Zeng, C. Qin, S. Y. Chen, F. Zhu, Z. R. Li, Y. Y. Jiang, W. P. Chen, Y. Z. Chen*. A protein network descriptor server and its use in studying protein, disease, metabolic and drug targeted networks. Brief Bioinform (当年影响因子: 8.399, 生物一区 TOP 期刊). 18(6): 1057-1070 (2017).
  43. P. Zhang, L. Tao, X. Zeng, C. Qin, S. Y. Chen, F. Zhu, S. Y. Yang, Z. R. Li, W. P. Chen, Y. Z. Chen*. PROFEAT update: a protein features web-server with added facility to compute network descriptors for studying omics-derived networks. J Mol Biol (当年影响因子: 4.632, 生物二区 TOP 期刊). 429(3): 416-425 (2017).
  44. H. Yang, C. Qin, Y. H. Li, L. Tao, J. Zhou, C. Y. Yu, F. Xu, Z. Chen, F. Zhu*, Y. Z. Chen*. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res (当年影响因子: 9.202, 生物一区 TOP 期刊). 44(D1): 1069-1074 (2016).
  45. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.71% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 0.87% in 2017.

  46. B. Li, J. Tang, Q. X. Yang, X. J. Cui, S. Li, S. J. Chen, Q. X. Cao, W. W. Xue, N. Chen, F. Zhu*. Performance evaluation and online realization of data-driven normalization methods used in LC/MS based untargeted metabolomics analysis. Sci Rep (当年影响因子: 5.228, 综合性二区期刊). 6: 38881 (2016).
  47. W. W. Xue, P. P. Wang, B. Li, Y. H. Li, X. F. Xu, F. Y. Yang, X. J. Yao, Y. Z. Chen, F. Xu*, F. Zhu*. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Phys Chem Chem Phys (当年影响因子: 4.493, 化学二区 TOP 期刊). 18(4): 3260-3271 (2016).
  48. 所构建方法的临床或实验验证:
    • The cocrystallized structure published (Nature. 532(7599):334-9, 2016) right after our publication was highly consistent with the drug-target binding mode discovered in this study.

  49. G. X. Zheng, W. W. Xue*, P. P. Wang, F. Y. Yang, B. Li, X. F. Li, Y. H. Li, X. J. Yao, F. Zhu*. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study. Sci Rep (当年影响因子: 5.228, 综合性二区期刊). 6: 26883 (2016).
  50. Y. H. Li, P. P. Wang, X. X. Li, C. Y. Yu, H. Yang, J. Zhou, W. W. Xue, J. Tan, F. Zhu*. The human kinome targeted by FDA approved multi-target drugs and combination products: a comparative study from the drug-target interaction network perspective. PLoS ONE (当年影响因子: 3.234, 生物三区期刊). 11(11): e0165737 (2016).
  51. J. Y. Xu, P. P. Wang, H. Yang, J. Zhou, Y. H. Li, X. X. Li, W. W. Xue*, C. Y. Yu, Y. B. Tian, F. Zhu*. Comparison of FDA approved kinase targets to clinical trial ones: insights from their system profiles and drug-target interaction networks. Biomed Res Int (当年影响因子: 2.476, 生物三区期刊). 2016: 2509385 (2016).
  52. Y. H. Li, J. Y. Xu, L. Tao, X. F. Li, S. Li, X. Zeng, S. Y. Chen, P. Zhang, C. Qin, C. Zhang, Z. Chen, F. Zhu*, Y. Z. Chen. SVM-Prot 2016: a web-server for machine learning prediction of protein functional families from sequence irrespective of similarity. PLoS ONE (当年影响因子: 3.234, 生物三区期刊). 11(8): e0155290 (2016).
  53. X. Zheng, S. Li, Z. L. Zang, J. T. Hu, J. Y. An, X. D. Pei, F. Zhu, W. H. Zhang*, H. Yang*. Evidence for possible role of toll-like receptor 3 mediating virus-induced progression of pituitary adenomas. Mol Cell Endocrinol (当年影响因子: 3.754, 医学二区期刊). 426: 22-32 (2016).
  54. L. Tao#, F. Zhu#, F. Xu, Z. Chen, Y. Y. Jiang*, Y. Z. Chen*. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacol Res (当年影响因子: 4.816, 医学二区期刊). 102: 123-131 (2015).
  55. L. Tao, P. Zhang, C. Qin, S. Y. Chen, C. Zhang, Z. Chen, F. Zhu, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. Adv Drug Deliver Rev (当年影响因子: 15.606, 医学一区 TOP 期刊). 86: 83-100 (2015).
  56. L. Tao, F. Zhu, C. Qin, C. Zhang, S. Y. Chen, P. Zhang, C. L. Zhang, C. Y. Tan, C. M. Gao, Z. Chen, Y. Y. Jiang*, Y. Z. Chen*. Clustered distribution of natural product leads of drugs in the chemical space as influenced by the privileged target-sites. Sci Rep (当年影响因子: 5.578, 综合性二区期刊). 5: 9325 (2015).
  57. P. P. Wang, F. Y. Yang, H. Yang, X. F. Xu, D. Liu, W. W. Xue, F. Zhu*. Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. Biomed Mater Eng (当年影响因子: 1.087, 工程四区期刊). 26(S1): 2233-2239 (2015).
  58. L. Tao, F. Zhu, C. Qin, C. Zhang, F. Xu, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. The nature's contribution to today's pharmacopeia. Nat Biotechnol (当年影响因子: 32.438, 工程一区 TOP 期刊). 32(10): 979-980 (2014).
  59. C. Zhang, C. Qin, L. Tao, F. Zhu, S. Y. Chen, P. Zhang, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. A resource for facilitating the development of tools in the education and implementation of genomics-informed personalized medicine. Clin Pharmacol Ther (当年影响因子: 7.390, 医学一区 TOP 期刊). 95(6): 590-591 (2014).
  60. C. Qin, C. Zhang, F. Zhu, F. Xu, S. Y. Chen, P. Zhang, Y. H. Li, S. Y. Yang, Y. Q. Wei, L. Tao*, Y. Z. Chen*. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res (当年影响因子: 8.278, 生物一区 TOP 期刊). 42(D1): 1118-1123 (2014).
  61. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.92% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2017.

  62. X. Liu, F. Zhu, X. H. Ma, Z. Shi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Predicting targeted polypharmacology for drug repositioning and multi-target drug discovery. Curr Med Chem (当年影响因子: 4.859, 医学二区期刊). 20(13): 1646-1661 (2013).
  63. F. Zhu, X. H. Ma, C. Qin, L. Tao, X. Liu, Z. Shi, C. L. Zhang, C. Y. Tan, Y. Z. Chen*, Y. Y. Jiang*. Drug discovery prospect from untapped species: indications from approved natural product drugs. PLoS ONE (当年影响因子: 4.411, 生物三区期刊). 7(7): e39782 (2012).
  64. X. H. Ma, F. Zhu, X. Liu, Z. Shi, J. X. Zhang, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Virtual screening methods as tools for drug lead discovery from large chemical libraries. Curr Med Chem (当年影响因子: 4.630, 医学二区期刊). 19(32): 5562-5571 (2012).
  65. J. X. Zhang, J. Jia, F. Zhu, X. H. Ma, B. C. Han, X. N. Wei, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Mol Biosyst (当年影响因子: 3.825, 生物三区期刊). 8(10): 2645-2656 (2012).
  66. F. Zhu, Z. Shi, C. Qin, L. Tao, X. Liu, F. Xu, L. Zhang, Y. Song, X. H. Liu, J. X. Zhang, B. C. Han, P. Zhang, Y. Z. Chen*. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (当年影响因子: 8.026, 生物一区 TOP 期刊). 40(D1): 1128-1136 (2012).
  67. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.62% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 0.31% in 2017.

    领域内专家评论:

    • "FACULTYof1000" as "the top 2% of published articles in biology and medicine" and "a most useful resource for scientists and companies working on drug discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations".
    • Prof. Chris Southan in his blog as "Therapeutic Target Database in PubChem".

  68. H. B. Rao*, Y. Y. Wang, X. Y. Zeng, X. X. Wang, Y. Liu, J. J. Yin, H. He, F. Zhu, Z. R. Li*. In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches. Chemometr Intell Lab (当年影响因子: 2.222, 工程三区期刊). 118: 271-279 (2012).
  69. H. B. Rao*, X. Y. Zeng, Y. Y. Wang, H. He, F. Zhu, Z. R. Li, Y. Z. Chen. Identification of DNA-Adduct formation of small molecules by molecular descriptors and machine learning methods. Mol Simul (当年影响因子: 1.215, 化学四区期刊). 38(4): 259-273 (2012).
  70. F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. H. Ma, J. Jia, Y. Tan, C. Cui, J. S. Lin, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A (当年影响因子: 9.432, 综合性一区 TOP 期刊). 108(31): 12943-12948 (2011).
  71. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 1.91% in 2017.
    领域内专家评论: 科技媒体及新闻报道:

  72. H. B. Rao#, F. Zhu#, G. B. Yang, Z. R. Li*, Y. Z. Chen. Update of PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequences. Nucleic Acids Res (当年影响因子: 7.836, 生物一区 TOP 期刊). 39(W1): 385-390 (2011).
  73. X. Liu, F. Zhu, X. H. Ma, L. Tao, J. X. Zhang, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. The therapeutic target database: an internet resource for the primary targets of approved, clinical trial and experimental drugs. Expert Opin Ther Targets (当年影响因子: 3.713, 生物二区期刊). 15(8): 903-912 (2011).
  74. F. Zhu, B. C. Han, P. Kumar, X. H. Liu, X. H. Ma, X. N. Wei, L. Huang, Y. F. Guo, L. Y. Han, C. J. Zheng, Y. Z. Chen*. Update of TTD: therapeutic target database. Nucleic Acids Res (当年影响因子: 7.479, 生物一区 TOP 期刊). 38(D1): 787-791 (2010).
  75. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.95% in 2017.

  76. F. Zhu, L. Y. Han, C. J. Zheng, B. Xie, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical and system profile of successful targets. J Pharmacol Exp Ther (当年影响因子: 3.867, 医学二区 TOP 期刊). 330(1): 304-315 (2009).
  77. 所构建方法的临床或实验验证:
    • Pasireotide targeting Somatostatin receptor 1 was approved by FDA in 2011.
    • Fingolimod targeting S1P receptor was approved by FDA in 2010.
    • Ecallantide targeting Plasma Kallikrein was approved by FDA in 2009.
    • Cinryze targeting C1 esterase was approved by FDA in 2009.
    • Icatibant targeting BK-2 receptor was approved by FDA in 2008.
    • Plerixafor targeting CXCR4 was approved by FDA in 2008.

  78. J. Jia, F. Zhu, X. H. Ma, Z. W. Cao, Y. X. Li, Y. Z. Chen*. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (当年影响因子: 23.308, 医学一区 TOP 期刊). 8(2): 111-128 (2009).
  79. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 1.13% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 1.39% in 2017.
  80. X. H. Ma, J. Jia, F. Zhu, Y. Xue, Z. R. Li, Y. Z. Chen*. Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. Comb Chem High Throughput Screen (当年影响因子: 2.344, 化学四区期刊). 12(4): 344-357 (2009).
  81. F. Zhu, L. Y. Han, X. Chen, H. H. Lin, S. Ong, B. Xie, H. L. Zhang, Y. Z. Chen*. Homology-free prediction of functional class of proteins and peptides by support vector machines. Curr Protein Pept Sci (当年影响因子: 3.976, 生物三区期刊). 9(1): 70-95 (2008).
  82. L. Y. Han, X. H. Ma, H. H. Lin, J. Jia, F. Zhu, Y. Xue, Z. R. Li, Z. W. Cao, Z. L. Ji, Y. Z. Chen*. A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. J Mol Graph Model (当年影响因子: 2.371, 生物四区期刊). 26(8): 1276-1286 (2008).
  83. L. Y. Han, C. J. Zheng, B. Xie, J. Jia, X. H. Ma, F. Zhu, H. H. Lin, X. Chen, Y. Z. Chen*. Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness. Drug Discov Today (当年影响因子: 7.755, 药学一区 TOP 期刊). 12(7-8): 304-313 (2007).
  84. H. H. Lin, L. Y. Han, C. W. Yap, Y. Xue, X. H. Liu, F. Zhu, Y. Z. Chen*. Prediction of factor Xa inhibitors by machine learning methods. J Mol Graph Model (当年影响因子: 2.333, 生物四区期刊). 26(2): 505-518 (2007).
  85. R. Li, Y. Chen, L. B. Cui, F. Zhu, J. Zhou, D. H. Liu*, S. Liu, X. S. Zhang. Effect of number of unit cells of FCC photonic crystal on property of band gaps. Acta Phys Sin (当年影响因子: 1.250, 物理四区期刊). 55(1): 188-191 (2006).



    承办或(参与)组织的学术会议

  1. F. Zhu is the Vice-chairman of the Symposium 24 Session-4 for The 31st Academic Annual Conference of the Chinese Chemical Society. Zhejiang University, Hangzhou, P. R. China (2018).
  2. F. Zhu is the Chairman of the Symposium IV Session -7 for Asian Federation for Pharmaceutical Sciences Conference 2017. Xiamen University, Xiamen, P. R. China (2017).
  3. F. Zhu is the Member of the Academic Committee for The 14th National Symposium of Computer & Computational Chemistry. Nanjing University, Nanjing, P. R. China (2017).
  4. F. Zhu is the Member of the Academic Committee for The Second CCF Bioinformatics Conference (CBC-2017). Central South University, Changsha, P. R. China (2017).
  5. F. Zhu is the Chairman of the sub-conference 103 (multi-target and protein-protein interaction) for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  6. F. Zhu is the Vice-chairman of the 6th theme (study on drug transporter and PK/PD) for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  7. F. Zhu is the Chair of the Organizing Committee and the Member of the Academic Committee for The 2nd Symposium on Bioinformatics and Drug Design. Chongqing University, Chongqing, P. R. China (2016).
  8. F. Zhu is the Member of the Academic Committee for The 13th National Symposium of Computer & Computational Chemistry. Sun Yat-sen University, Guangzhou, P. R. China (2015).
  9. F. Zhu is the Member of the Organizing Committee for International Symposium on Natural Product Synthesis and Innovative Process Methods for Drug Manufacture. Chongqing University, Chongqing, P. R. China (2012).



    国际国内学术会议邀请报告

  1. F. Zhu*. Clinical target discovery inspired from artificial intelligence. Invited keynote speaker of domestic conference for 1st West Lake Clinical Research and Evaluation Conference. The First Affiliated Hospital, Zhejiang University, Hangzhou, P. R. China (2018).
  2. F. Zhu*. Progression of first-in-class drugs and their corresponding targets. Invited speaker of domestic conference for The 10th National Symposium of Genetics Society of China. Nanjing Agricultural University, Nanjing, P. R. China (2018).
  3. F. Zhu*. Proteomics-directed novel target discovery. Invited speaker of domestic conference for The 2018 Annual Symposium of the Shanghai Association of Chinese Integrative Medicine. Shanghai University of Traditional Chinese Medicine, Shanghai, P. R. China (2018).
  4. F. Zhu*. Progression-speed differentiating features of the targets of first-in-class drugs. Invited speaker of domestic conference for The 14th Symposium of the Chinese Pharmaceutical Association for Youth Pharmacologist. Chinese Pharmaceutical Association, Hangzhou, P. R. China (2018).
  5. F. Zhu*. Identification of key factors indicating the progression timelines of novel drug targets. Invited keynote speaker of international conference for 11th China-Japan Symposium on Molecular Drug Design and Development. Zhejiang University and Chinese Academy of Medical Sciences & Peking Union Medical College, Shaoxing, P. R. China (2018).
  6. F. Zhu*. Target discovery using proteomic and system biological data. Invited speaker of international conference for The 2nd Worldwide Chinese Computational Biology and Molecular Simulation Conference. Sun Yat-sen University, Guangzhou, P. R. China (2018).
  7. F. Zhu*. OMICs based innovative drug target discovery. Invited speaker of domestic conference for The 31st Academic Annual Conference of the Chinese Chemical Society. Zhejiang University, Hangzhou, P. R. China (2018).
  8. F. Zhu*. Next Generation Innovative Therapeutic Target from NOREVA. Invited speaker of international conference for Asian Federation for Pharmaceutical Sciences Conference 2017. Xiamen University, Xiamen, P. R. China (2017).
  9. F. Zhu*. Target Identification Assisted by Big-data Analyzing Tools. Invited speaker of domestic conference for The 14th National Symposium of Computer & Computational Chemistry. Nanjing University, Nanjing, P. R. China (2017).
  10. F. Zhu*. Drug Design and Big-data Platform. Invited speaker of domestic conference for The 5th Academic Forum for Postgraduates. Sichuan University, Chengdu, P. R. China (2017).
  11. F. Zhu*. Identification of Next Generation Innovative Therapeutic Target from OMICs Data. Invited keynote speaker of domestic conference for 2017 Symposium on Pharmaceutical Chemistry of the Yangtze River Delta Metropolitan Region. Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, P. R. China (2017).
  12. W. W. Xue* and F. Zhu*. What Contributes to SNRIs’ Dual-targeting Mechanism? The Key Role Played by TM6 Domain. Invited speaker of domestic conference for The Second Conference on Innovative Drug Research and Application. Nanjing Biotech and Pharmaceutical Valley, Nanjing, P. R. China (2017).
  13. F. Zhu*. Normalization and evaluation of metabolomics and proteomics data from multiple perspectives. Invited speaker of domestic conference for Bioinformatics and Intelligent Information Processing Academic Conference 2017 (BIIP2017). Shanghai Jiao Tong University, Shanghai, P. R. China (2017).
  14. F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Invited speaker of domestic conference for The Fifth Young Scholars Forum for Interdisciplinary Researches in Mathematics, Computer Sciences and Biological Sciences. Academy of Mathematics and System Science, Chinese Academy of Sciences, Beijing, P. R. China (2017).
  15. F. Zhu*. Normalization and evaluation of MS-based metabolomics data from multiple perspectives. Invited speaker of domestic conference for The 2017 (the second) Conference on Precision and Future Medicine. Zhejiang University, Hangzhou, P. R. China (2017).
  16. F. Zhu*. Large-scale Metabolomics Data Analysis. Invited speaker of domestic conference for China Society of Biotechnology Young Scientists Forum II . South China University of Technology, Guangzhou, P. R. China (2017).
  17. F. Zhu*. Bioinformatics Strategies in Precision Medicine. Invited speaker of international conference for The 2016 Symposium of Guanghua Young Distinguished Scholars . Fudan University, Shanghai, P. R. China (2016).
  18. F. Zhu*. Insight into the pathogenesis of pituitary adenomas by analyzing trans-omic data. Invited speaker of international conference for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  19. F. Zhu*. Metabolomics meta-analysis by MMEASE. Invited speaker of international conference for the 1st International Symposium on Targeted Therapeutics and Molecular Medicine (ISTTMM 2016). Chongqing University of Arts and Sciences, Chongqing, P. R. China (2016).
  20. W. W. Xue and F. Zhu*. Molecular dynamics study and comparison on the binding modes of SSRIs, sNRIs and SNRIs antidepressants. Invited speaker of international conference for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  21. G. X. Zheng, W. W. Xue and F. Zhu*. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors from molecular dynamics study. Invited speaker of international conference for The 4th International Conference on Molecular Simulation (ICMS 2016). Shanghai Jiao Tong University, Shanghai, P. R. China (2016).
  22. F. Zhu*. Normalization and Meta-analysis of Metabolomics Data. Invited speaker of domestic conference for The 7th National Conference on Bioinformatics & System Biology. University of Electronic Science and Technology of China, Chengdu, P. R. China (2016).
  23. F. Zhu*. Insight into the Pathogenesis of Pituitary Adenomas by Meta-analysis of Transcriptomic and Metabolomic Data. Invited speaker of domestic conference for The 2016 Conference on Precision Medicine. Xian Jiaotong University, Xian, P. R. China (2016).
  24. F. Zhu*. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Invited speaker of international conference for The 12th Sino-US Chemistry Professors Conference. Sun Yat-sen University, Guangzhou, P. R. China (2016).
  25. F. Zhu*. Discovering the stable marker identification methods for metabonomics study. Invited speaker of international conference for The 2016 Symposium of International Young Distinguished Scholars. Tongji University, Shanghai, P. R. China (2016).
  26. F. Zhu*. Design of multi-target anticancer drugs by analyzing the protein-protein interaction network of cancer. Invited speaker of domestic conference for The 2nd Symposium on Bioinformatics and Drug Design. Chongqing University, Chongqing, P. R. China (2016).
  27. F. Zhu*. Meta-analysis of Metabolomic data. Invited speaker of domestic conference for The 2016 Conference on Bioinformatics and Intelligent Information Processing (BIIP2016). Jilin University, Jilin, P. R. China (2016).
  28. F. Zhu*. MMEASE: a web-server for Meta-analysis of Metabolomic data by Enhanced metabolite Annotation, marker Selection and Enrichment analysis. Invited speaker of domestic conference for The 30th Academic Annual Conference of the Chinese Chemical Society. Dalian University of Technology, Dalian, P. R. China (2016).
  29. F. Zhu*. Identifying the metabonomics biomarkers. Invited speaker of domestic conference for The 2016 Academic Salon of Shanghai Society for Bioinformatics. Fudan University, Shanghai, P. R. China (2016).
  30. F. Zhu*. Insight into the pathogenesis of pituitary adenomas by meta-analysis of transcriptomic data. Invited speaker of domestic conference for The 2016 Symposium of Big Data and Precision Biomedical Informatics. Shanghai Jiao Tong University, Shanghai, P. R. China (2016).
  31. W. W. Xue and F. Zhu*. Identification of multi-target drug against remote target pair using combinatorial support vector mechine method. Invited speaker of domestic conference for The 13th National Symposium of Computer & Computational Chemistry. Sun Yat-sen University, Guangzhou, P. R. China (2015).
  32. F. Zhu*. Future bioprospecting: from the clustered patterns of species origins of nature-derived drugs. Invited speaker of international conference for The 6th International Conference of Molecular Simulation and Applied Information Technologies (6th-ICMS&I). China Pharmaceutical University, Nanjing, P. R. China (2012).
  33. F. Zhu*. Drug discovery prospect from untapped species: indications from approved natural product drugs. Invited speaker of international conference for International Symposium on Natural Product Synthesis and Innovative Process Methods for Drug Manufacture. Chongqing University, Chongqing, P. R. China (2012).
  34. F. Zhu*. Identification of next generation innovative therapeutic targets: clues from genetic, structural, physicochemical and system profile of successful ones. Invited speaker of international conference for Singapore Symposium on Computational Biology 2009 (SYMBIO2009). National University of Singapore, Singapore, Singapore (2009).



    学术访问与交流

  1. F. Zhu*. Bioinformatics tools applied to the research field of brain science. Invited academic visit by Prof. Bo-Chu Wang to Bioengineering College, Chongqing University, Chongqing, P. R. China (2016).
  2. F. Zhu*. Comprehensive assessment of the popular normalization methods used in metabonomics study. Invited academic visit by Prof. Yu-Yang Jiang to Graduate School at Shenzhen, Tsinghua University, Shenzhen, P. R. China (2016).
  3. W. W. Xue and F. Zhu*. Extension of bioinformatics to the fields of brain sciences: metabonomics study of pituitary adenomas and design of multi-target antidepressants. Invited academic visit by Prof. Han-Bing Rao to Faculty of Science, Sichuan Agricultural University, Yaan, P. R. China (2016).
  4. W. W. Xue and F. Zhu*. Design of multi-target anticancer drugs by analyzing the protein-protein interaction network of cancer. Invited academic visit by Prof. Xiao-Jun Yao to School of Pharmacy, Lanzhou University, Lanzhou, P. R. China (2014).
  5. F. Zhu*. Computer-aided drug design based on the complex biological network of cancer. Invited academic visit by Prof. Cheng-Zhi Huang to College of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, P. R. China (2014).
  6. F. Zhu*. Identification of multi-target anticancer leads using combinatorial machine learning methods. Invited academic visit by Prof. Wei Wang to State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, P. R. China (2013).
  7. F. Zhu*. Design of anticancer leads and testing of their bioactivities. Invited academic visit by Prof. Da-He Liu to Department of Physics, Beijing Normal University, Beijing, P. R. China (2013).
  8. F. Zhu*. Find target and design bullet for the complex network disease - cancer. Invited academic visit by Prof. Ying Xue to College of Chemistry, Sichuan University, Chengdu, P. R. China (2013).
  9. F. Zhu*. Targets! Bullets! Computer-aided drug design from the network medicine perspective. Invited academic visit by Prof. Han-Bing Rao to Faculty of Science, Sichuan Agricultural University, Yaan, P. R. China (2013).
  10. F. Zhu*. Bioinformatics identification of anticancer drug targets. Invited academic visit by Prof. Kun-Xian Shu to School of Bioinformatics, Chongqing University of Posts and Telecommunications, Chongqing, P. R. China (2013).
  11. F. Zhu*. Clustered patterns of species origins of active ingredients in the traditional chinese medicine. Invited academic visit by Prof. Qi-Ni Qian to Chongqing Institute of Medicinal Plant Cultivation, Chongqing Institute of Medicinal Plant Cultivation, Chongqing, P. R. China (2013).

IDRB: Innovative Drug Research and Bioinformatics Group

321439   visits since 2012
创新药物研究与生物信息学实验室 (IDRB)   版权所有
地址:浙江省杭州市西湖区余杭塘路866号,浙江大学紫金港校区;邮编:310058
联系电话:0571-88208444

本网站最新更新时间: